prikaz prve stranice dokumenta In situ gelling nanosuspension as an advanced platform for fluticasone propionate nasal delivery
Pristup korisnicima matične ustanove
Znanstveni rad - Izvorni znanstveni rad
In situ gelling nanosuspension as an advanced platform for fluticasone propionate nasal delivery
European Journal of Pharmaceutics and Biopharmaceutics, 175 (2022); 27-42. https://doi.org/10.1016/j.ejpb.2022.04.009
Nižić Nodilo, Laura; Perkušić, Mirna; Ugrina, Ivo; Špoljarić, Drago; Jakobušić Brala, Cvijeta; Amidžić Klarić, Daniela; Lovrić, Jasmina; Saršon, Vesna; Safundžić Kučuk, Maša; Zadravec, Dijana; Kalogjera, Livije; Pepić, Ivan; Hafner, Anita

Citirajte ovaj rad

Nižić Nodilo, L., Perkušić, M., Ugrina, I., Špoljarić, D., Jakobušić Brala, C., Amidžić Klarić, D. ... Hafner, A. (2022). In situ gelling nanosuspension as an advanced platform for fluticasone propionate nasal delivery. European Journal of Pharmaceutics and Biopharmaceutics, 175., 27-42. doi: 10.1016/j.ejpb.2022.04.009

Nižić Nodilo, Laura, et al. "In situ gelling nanosuspension as an advanced platform for fluticasone propionate nasal delivery." European Journal of Pharmaceutics and Biopharmaceutics, vol. 175, 2022, str. 27-42. https://doi.org/10.1016/j.ejpb.2022.04.009

Nižić Nodilo, Laura, Mirna Perkušić, Ivo Ugrina, Drago Špoljarić, Cvijeta Jakobušić Brala, Daniela Amidžić Klarić, Jasmina Lovrić, et al. "In situ gelling nanosuspension as an advanced platform for fluticasone propionate nasal delivery." European Journal of Pharmaceutics and Biopharmaceutics 175 (2022): 27-42. https://doi.org/10.1016/j.ejpb.2022.04.009

Nižić Nodilo, L., et al. (2022) 'In situ gelling nanosuspension as an advanced platform for fluticasone propionate nasal delivery', European Journal of Pharmaceutics and Biopharmaceutics, 175, str. 27-42. doi: 10.1016/j.ejpb.2022.04.009

Nižić Nodilo L, Perkušić M, Ugrina I, Špoljarić D, Jakobušić Brala C, Amidžić Klarić D, i sur.. In situ gelling nanosuspension as an advanced platform for fluticasone propionate nasal delivery. European Journal of Pharmaceutics and Biopharmaceutics [Internet]. 2022. [pristupljeno 07.12.2024.];175:27-42. doi: 10.1016/j.ejpb.2022.04.009

L. Nižić Nodilo, et al., "In situ gelling nanosuspension as an advanced platform for fluticasone propionate nasal delivery", European Journal of Pharmaceutics and Biopharmaceutics, vol. 175, str. 27-42, 2022. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:220:438756. [Citirano: 07.12.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:220:438756
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)In situ gelling nanosuspension as an advanced platform for fluticasone propionate nasal delivery
AutorLaura Nižić Nodilo
AutorMirna Perkušić
AutorIvo Ugrina
AutorDrago Špoljarić
AutorCvijeta Jakobušić Brala
AutorDaniela Amidžić Klarić
AutorJasmina Lovrić
AutorVesna Saršon
AutorMaša Safundžić Kučuk
AutorDijana Zadravec
AutorLivije Kalogjera
AutorIvan Pepić
AutorAnita Hafner
Autorova ustanova(Klinički bolnički centar Sestre milosrdnice)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Otorinolaringologija
Sažetak (engleski)
In this work we present the development of in situ gelling nanosuspension as advanced form for fluticasone propionate nasal delivery. Drug nanocrystals were prepared by wet milling technique. Incorporation of drug nanocrystals into polymeric in situ gelling system with pectin and sodium hyaluronate as constitutive polymers was fine-tuned attaining appropriate formulation surface tension, viscosity and gelling ability. Drug nanonisation improved the release profile and enhanced formulation mucoadhesive properties. QbD approach combining formulation and administration parameters resulted in optimised nasal deposition profile, with 51.8% of the dose deposited in the middle meatus, the critical region in the treatment of rhinosinusitis and nasal polyposis. Results obtained in biocompatibility and physico-chemical stability studies confirmed the leading formulation potential for safe and efficient nasal corticosteroid delivery.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaEuropean Journal of Pharmaceutics and Biopharmaceutics
Brojčani podacivol. 175, str. 27-42
p-ISSN0939-6411
DOIhttps://doi.org/10.1016/j.ejpb.2022.04.009
URN:NBNurn:nbn:hr:220:438756
Datum objave publikacije2022
URL dokumentahttps://www.sciencedirect.com/science/article/abs/pii/S0939641122000819?via%3Dihub
Vrsta resursaTekst
Prava pristupaInstitucijski pristup
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2023-12-15 10:51:47